TY - JOUR
T1 - Efectos antiproliferativos in vitro y acciones antitumorales in vivo de la dafnetina en diferentes células tumorales
AU - Alejandro Jiménez-Orozco, F.
AU - Ranđelović, Ivan
AU - Hegedüs, Zita
AU - Vega-Lopez, Armando
AU - Martínez-Flores, Francisco
AU - Tóvarí, József
N1 - Publisher Copyright:
© 2020 Academia Mexicana de Cirugía.
PY - 2020
Y1 - 2020
N2 - Background: The anti-inflammatory effects of daphnetin (7,8-dihidroxicoumarin) have been well-documented, but the potential of daphnetin as an anticancer agent is controversial and remains insufficiently explored. Material and methods: In this work, we evaluated the in vitro anti-proliferative effect of daphnetin in three cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-razolium bromide assays, as well as its in vivo antitumor effect in four different types of mouse tumor. Results: With a correlation between in vitro and in vivo results, the tested cell types have different sensitivity to the compound. The following cell lines are arranged according to the in vitro anti-proliferative potency of daphnetin: B16 melanoma cells (inhibitory concentrations 50 [IC50] = 54 ± 2.8 μM) > mitoxantrone (MXT) breast adenocarcinoma cells (IC50 = 74 ± 6.4 μM) > C26 colon carcinoma cells (IC50 = 108 ± 7.3 μM). In vivo, the optimal antitumor dose of daphnetin was 40 mg/kg and the magnitudes of inhibition were the following: B16 tumor (48%) > MXT tumor (40%) > S180 fibrosarcoma tumor (30%) > C26 tumor (20%). Conclusion: Our results indicate that daphnetin might have an impact as adjuvant to improve the effectiveness of conventional chemotherapy.
AB - Background: The anti-inflammatory effects of daphnetin (7,8-dihidroxicoumarin) have been well-documented, but the potential of daphnetin as an anticancer agent is controversial and remains insufficiently explored. Material and methods: In this work, we evaluated the in vitro anti-proliferative effect of daphnetin in three cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-razolium bromide assays, as well as its in vivo antitumor effect in four different types of mouse tumor. Results: With a correlation between in vitro and in vivo results, the tested cell types have different sensitivity to the compound. The following cell lines are arranged according to the in vitro anti-proliferative potency of daphnetin: B16 melanoma cells (inhibitory concentrations 50 [IC50] = 54 ± 2.8 μM) > mitoxantrone (MXT) breast adenocarcinoma cells (IC50 = 74 ± 6.4 μM) > C26 colon carcinoma cells (IC50 = 108 ± 7.3 μM). In vivo, the optimal antitumor dose of daphnetin was 40 mg/kg and the magnitudes of inhibition were the following: B16 tumor (48%) > MXT tumor (40%) > S180 fibrosarcoma tumor (30%) > C26 tumor (20%). Conclusion: Our results indicate that daphnetin might have an impact as adjuvant to improve the effectiveness of conventional chemotherapy.
KW - Daphnetin. Coumarins. Antiproliferation. Antitumor activity. Tumor chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85097035433&partnerID=8YFLogxK
U2 - 10.24875/CIRU.20000197
DO - 10.24875/CIRU.20000197
M3 - Artículo
C2 - 33254179
AN - SCOPUS:85097035433
SN - 0009-7411
VL - 88
SP - 765
EP - 771
JO - Cirugia y Cirujanos (English Edition)
JF - Cirugia y Cirujanos (English Edition)
IS - 6
ER -